Global and China Multiple Sclerosis Drugs Market Insights, Forecast to 2027

Publisher Name :
Date: 23-Aug-2021
No. of pages: 135
Inquire Before Buying

Multiple Sclerosis Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Sclerosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.

For China market, this report focuses on the Multiple Sclerosis Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type

- Injectable Medications

- Oral Medications

- Others

Segment by Application

- Adults

- Children

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Biogen

- Sanofi

- Novartis

- Teva

- Merck KGaA

- Bayer

- ACORDA

- Mallinckrodt

Global and China Multiple Sclerosis Drugs Market Insights, Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Multiple Sclerosis Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Type
1.2.2 Injectable Medications
1.2.3 Oral Medications
1.2.4 Others
1.3 Market by Application
1.3.1 Global Multiple Sclerosis Drugs Market Size Growth Rate by Application
1.3.2 Adults
1.3.3 Children
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Multiple Sclerosis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Multiple Sclerosis Drugs Revenue 2016-2027
2.1.2 Global Multiple Sclerosis Drugs Sales 2016-2027
2.2 Global Multiple Sclerosis Drugs, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Multiple Sclerosis Drugs Historical Market Size by Region (2016-2021)
2.3.1 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Multiple Sclerosis Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Multiple Sclerosis Drugs Sales Forecast by Region (2022-2027)
2.4.2 Global Multiple Sclerosis Drugs Revenue Forecast by Region (2022-2027)
3 Global Multiple Sclerosis Drugs Competitor Landscape by Players
3.1 Global Top Multiple Sclerosis Drugs Manufacturers by Sales
3.1.1 Global Multiple Sclerosis Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Multiple Sclerosis Drugs Manufacturers by Revenue
3.2.1 Key Multiple Sclerosis Drugs Manufacturers Covered: Ranking by Revenue
3.2.2 Global Multiple Sclerosis Drugs Revenue by Manufacturers (2016-2021)
3.2.3 Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Multiple Sclerosis Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Multiple Sclerosis Drugs Revenue in 2020
3.2.6 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Multiple Sclerosis Drugs Price by Manufacturers
3.4 Global Multiple Sclerosis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Multiple Sclerosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Multiple Sclerosis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Multiple Sclerosis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Multiple Sclerosis Drugs Market Size by Type (2016-2021)
4.1.1 Global Multiple Sclerosis Drugs Sales by Type (2016-2021)
4.1.2 Global Multiple Sclerosis Drugs Revenue by Type (2016-2021)
4.1.3 Multiple Sclerosis Drugs Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Multiple Sclerosis Drugs Market Size Forecast by Type (2022-2027)
4.2.1 Global Multiple Sclerosis Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Multiple Sclerosis Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Multiple Sclerosis Drugs Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Multiple Sclerosis Drugs Market Size by Application (2016-2021)
5.1.1 Global Multiple Sclerosis Drugs Sales by Application (2016-2021)
5.1.2 Global Multiple Sclerosis Drugs Revenue by Application (2016-2021)
5.1.3 Multiple Sclerosis Drugs Price by Application (2016-2021)
5.2 Multiple Sclerosis Drugs Market Size Forecast by Application (2022-2027)
5.2.1 Global Multiple Sclerosis Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Multiple Sclerosis Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Multiple Sclerosis Drugs Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
6.1.1 China Multiple Sclerosis Drugs Sales YoY Growth 2016-2027
6.1.2 China Multiple Sclerosis Drugs Revenue YoY Growth 2016-2027
6.1.3 China Multiple Sclerosis Drugs Market Share in Global Market 2016-2027
6.2 China Multiple Sclerosis Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Multiple Sclerosis Drugs Players by Sales (2016-2021)
6.2.2 China Top Multiple Sclerosis Drugs Players by Revenue (2016-2021)
6.3 China Multiple Sclerosis Drugs Historic Market Review by Type (2016-2021)
6.3.1 China Multiple Sclerosis Drugs Sales Market Share by Type (2016-2021)
6.3.2 China Multiple Sclerosis Drugs Revenue Market Share by Type (2016-2021)
6.3.3 China Multiple Sclerosis Drugs Price by Type (2016-2021)
6.4 China Multiple Sclerosis Drugs Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Multiple Sclerosis Drugs Sales Forecast by Type (2022-2027)
6.4.2 China Multiple Sclerosis Drugs Revenue Forecast by Type (2022-2027)
6.4.3 China Multiple Sclerosis Drugs Price Forecast by Type (2022-2027)
6.5 China Multiple Sclerosis Drugs Historic Market Review by Application (2016-2021)
6.5.1 China Multiple Sclerosis Drugs Sales Market Share by Application (2016-2021)
6.5.2 China Multiple Sclerosis Drugs Revenue Market Share by Application (2016-2021)
6.5.3 China Multiple Sclerosis Drugs Price by Application (2016-2021)
6.6 China Multiple Sclerosis Drugs Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Multiple Sclerosis Drugs Sales Forecast by Application (2022-2027)
6.6.2 China Multiple Sclerosis Drugs Revenue Forecast by Application (2022-2027)
6.6.3 China Multiple Sclerosis Drugs Price Forecast by Application (2022-2027)
7 North America
7.1 North America Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
7.2 North America Multiple Sclerosis Drugs Market Facts & Figures by Country
7.2.1 North America Multiple Sclerosis Drugs Sales by Country (2016-2021)
7.2.2 North America Multiple Sclerosis Drugs Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
8.2 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Region
8.2.1 Asia Pacific Multiple Sclerosis Drugs Sales by Region (2016-2021)
8.2.2 Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
9.2 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country
9.2.1 Europe Multiple Sclerosis Drugs Sales by Country (2016-2021)
9.2.2 Europe Multiple Sclerosis Drugs Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country
10.2.1 Latin America Multiple Sclerosis Drugs Sales by Country (2016-2021)
10.2.2 Latin America Multiple Sclerosis Drugs Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Multiple Sclerosis Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2016-2021)
11.2.2 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Biogen
12.1.1 Biogen Corporation Information
12.1.2 Biogen Description and Business Overview
12.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Biogen Multiple Sclerosis Drugs Products Offered
12.1.5 Biogen Recent Development
12.2 Sanofi
12.2.1 Sanofi Corporation Information
12.2.2 Sanofi Description and Business Overview
12.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Sanofi Multiple Sclerosis Drugs Products Offered
12.2.5 Sanofi Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Description and Business Overview
12.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Novartis Multiple Sclerosis Drugs Products Offered
12.3.5 Novartis Recent Development
12.4 Teva
12.4.1 Teva Corporation Information
12.4.2 Teva Description and Business Overview
12.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Teva Multiple Sclerosis Drugs Products Offered
12.4.5 Teva Recent Development
12.5 Merck KGaA
12.5.1 Merck KGaA Corporation Information
12.5.2 Merck KGaA Description and Business Overview
12.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Merck KGaA Multiple Sclerosis Drugs Products Offered
12.5.5 Merck KGaA Recent Development
12.6 Bayer
12.6.1 Bayer Corporation Information
12.6.2 Bayer Description and Business Overview
12.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Bayer Multiple Sclerosis Drugs Products Offered
12.6.5 Bayer Recent Development
12.7 ACORDA
12.7.1 ACORDA Corporation Information
12.7.2 ACORDA Description and Business Overview
12.7.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 ACORDA Multiple Sclerosis Drugs Products Offered
12.7.5 ACORDA Recent Development
12.8 Mallinckrodt
12.8.1 Mallinckrodt Corporation Information
12.8.2 Mallinckrodt Description and Business Overview
12.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Mallinckrodt Multiple Sclerosis Drugs Products Offered
12.8.5 Mallinckrodt Recent Development
12.11 Biogen
12.11.1 Biogen Corporation Information
12.11.2 Biogen Description and Business Overview
12.11.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Biogen Multiple Sclerosis Drugs Products Offered
12.11.5 Biogen Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Multiple Sclerosis Drugs Industry Trends
13.2 Multiple Sclerosis Drugs Market Drivers
13.3 Multiple Sclerosis Drugs Market Challenges
13.4 Multiple Sclerosis Drugs Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Multiple Sclerosis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Global Multiple Sclerosis Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Injectable Medications
Table 3. Major Manufacturers of Oral Medications
Table 4. Major Manufacturers of Others
Table 5. Global Multiple Sclerosis Drugs Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 6. Global Multiple Sclerosis Drugs Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Multiple Sclerosis Drugs Sales by Regions (2016-2021) & (K Units)
Table 8. Global Multiple Sclerosis Drugs Sales Market Share by Regions (2016-2021)
Table 9. Global Multiple Sclerosis Drugs Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Multiple Sclerosis Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 11. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Multiple Sclerosis Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Multiple Sclerosis Drugs Sales by Manufacturers (2016-2021) (K Units)
Table 15. Global Multiple Sclerosis Drugs Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Multiple Sclerosis Drugs Manufacturers by Revenue (US$ Million) in 2020
Table 17. Multiple Sclerosis Drugs Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Multiple Sclerosis Drugs Revenue Share by Manufacturers (2016-2021)
Table 19. Global Multiple Sclerosis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Drugs as of 2020)
Table 21. Key Manufacturers Multiple Sclerosis Drugs Price (2016-2021) (USD/Unit)
Table 22. Multiple Sclerosis Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Multiple Sclerosis Drugs Product Type
Table 24. Date of International Manufacturers Enter into Multiple Sclerosis Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Multiple Sclerosis Drugs Sales by Type (2016-2021) (K Units)
Table 27. Global Multiple Sclerosis Drugs Sales Share by Type (2016-2021)
Table 28. Global Multiple Sclerosis Drugs Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Multiple Sclerosis Drugs Revenue Share by Type (2016-2021)
Table 30. Multiple Sclerosis Drugs Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 31. Global Multiple Sclerosis Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 32. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Multiple Sclerosis Drugs Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Multiple Sclerosis Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 36. Global Multiple Sclerosis Drugs Sales by Application (2016-2021) (K Units)
Table 37. Global Multiple Sclerosis Drugs Sales Share by Application (2016-2021)
Table 38. Global Multiple Sclerosis Drugs Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Multiple Sclerosis Drugs Revenue Share by Application (2016-2021)
Table 40. Multiple Sclerosis Drugs Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 41. Global Multiple Sclerosis Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 42. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Multiple Sclerosis Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Multiple Sclerosis Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 46. China Multiple Sclerosis Drugs Sales (K Units) of Key Companies (2016-2021)
Table 47. China Multiple Sclerosis Drugs Sales Share by Company (2016-2021)
Table 48. China Multiple Sclerosis Drugs Revenue (US$ Million) by Company (2016-2021)
Table 49. China Multiple Sclerosis Drugs Revenue Share by Company (2016-2021)
Table 50. China Multiple Sclerosis Drugs Sales (K Units) by Type (2016-2021)
Table 51. China Multiple Sclerosis Drugs Sales Share by Type (2016-2021)
Table 52. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. China Multiple Sclerosis Drugs Price (USD/Unit) by Type (2016-2021)
Table 54. China Multiple Sclerosis Drugs Sales (K Units) by Type (2022-2027)
Table 55. China Multiple Sclerosis Drugs Sales Share by Type (2022-2027)
Table 56. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. China Multiple Sclerosis Drugs Revenue Share by Type (2022-2027)
Table 58. China Multiple Sclerosis Drugs Price (USD/Unit) by Type (2022-2027)
Table 59. China Multiple Sclerosis Drugs Sales (K Units) by Application (2016-2021)
Table 60. China Multiple Sclerosis Drugs Sales Share by Application (2016-2021)
Table 61. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. China Multiple Sclerosis Drugs Price (USD/Unit) by Application (2016-2021)
Table 63. China Multiple Sclerosis Drugs Sales (K Units) by Application (2022-2027)
Table 64. China Multiple Sclerosis Drugs Sales Share by Application (2022-2027)
Table 65. China Multiple Sclerosis Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. China Multiple Sclerosis Drugs Revenue Share by Application (2022-2027)
Table 67. China Multiple Sclerosis Drugs Price (USD/Unit) by Application (2022-2027)
Table 68. North America Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units)
Table 69. North America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021)
Table 70. North America Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2016-2021) & (K Units)
Table 73. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2021)
Table 76. Europe Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units)
Table 77. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021)
Table 78. Europe Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021)
Table 80. Latin America Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units)
Table 81. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units)
Table 85. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021)
Table 88. Biogen Corporation Information
Table 89. Biogen Description and Business Overview
Table 90. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Biogen Multiple Sclerosis Drugs Product
Table 92. Biogen Recent Development
Table 93. Sanofi Corporation Information
Table 94. Sanofi Description and Business Overview
Table 95. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Sanofi Product
Table 97. Sanofi Recent Development
Table 98. Novartis Corporation Information
Table 99. Novartis Description and Business Overview
Table 100. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Novartis Product
Table 102. Novartis Recent Development
Table 103. Teva Corporation Information
Table 104. Teva Description and Business Overview
Table 105. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. Teva Product
Table 107. Teva Recent Development
Table 108. Merck KGaA Corporation Information
Table 109. Merck KGaA Description and Business Overview
Table 110. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Merck KGaA Product
Table 112. Merck KGaA Recent Development
Table 113. Bayer Corporation Information
Table 114. Bayer Description and Business Overview
Table 115. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Bayer Product
Table 117. Bayer Recent Development
Table 118. ACORDA Corporation Information
Table 119. ACORDA Description and Business Overview
Table 120. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. ACORDA Product
Table 122. ACORDA Recent Development
Table 123. Mallinckrodt Corporation Information
Table 124. Mallinckrodt Description and Business Overview
Table 125. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Mallinckrodt Product
Table 127. Mallinckrodt Recent Development
Table 128. Multiple Sclerosis Drugs Market Trends
Table 129. Multiple Sclerosis Drugs Market Drivers
Table 130. Multiple Sclerosis Drugs Market Challenges
Table 131. Multiple Sclerosis Drugs Market Restraints
Table 132. Multiple Sclerosis Drugs Customers List
Table 133. Multiple Sclerosis Drugs Distributors List
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Multiple Sclerosis Drugs Product Picture
Figure 2. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2020 & 2027
Figure 3. Injectable Medications Product Picture
Figure 4. Oral Medications Product Picture
Figure 5. Others Product Picture
Figure 6. Global Multiple Sclerosis Drugs Sales Market Share by Application in 2020 & 2027
Figure 7. Adults
Figure 8. Children
Figure 9. Multiple Sclerosis Drugs Report Years Considered
Figure 10. Global Multiple Sclerosis Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Multiple Sclerosis Drugs Market Size 2016-2027 (US$ Million)
Figure 12. Global Multiple Sclerosis Drugs Sales 2016-2027 (K Units)
Figure 13. Global Multiple Sclerosis Drugs Market Size Market Share by Region: 2021 Versus 2027
Figure 14. Global Multiple Sclerosis Drugs Sales Market Share by Region (2016-2021)
Figure 15. Global Multiple Sclerosis Drugs Sales Market Share by Region in 2020
Figure 16. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2021)
Figure 17. Global Multiple Sclerosis Drugs Revenue Market Share by Region in 2020
Figure 18. Global Multiple Sclerosis Drugs Sales Share by Manufacturer in 2020
Figure 19. The Top 10 and 5 Players Market Share by Multiple Sclerosis Drugs Revenue in 2020
Figure 20. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 21. Global Multiple Sclerosis Drugs Sales Market Share by Type (2016-2021)
Figure 22. Global Multiple Sclerosis Drugs Sales Market Share by Type in 2020
Figure 23. Global Multiple Sclerosis Drugs Revenue Market Share by Type (2016-2021)
Figure 24. Global Multiple Sclerosis Drugs Revenue Market Share by Type in 2020
Figure 25. Global Multiple Sclerosis Drugs Sales Market Share by Application (2016-2021)
Figure 26. Global Multiple Sclerosis Drugs Sales Market Share by Application in 2020
Figure 27. Global Multiple Sclerosis Drugs Revenue Market Share by Application (2016-2021)
Figure 28. Global Multiple Sclerosis Drugs Revenue Market Share by Application in 2020
Figure 29. China Multiple Sclerosis Drugs Sales Growth Rate 2016-2027 (K Units)
Figure 30. China Multiple Sclerosis Drugs Revenue Growth Rate 2016-2027 (US$ Million)
Figure 31. China Multiple Sclerosis Drugs Market Share in Global Market 2016-2027
Figure 32. China 5 and 10 Largest Multiple Sclerosis Drugs Players Market Share by Revenue in Multiple Sclerosis Drugs in 2020
Figure 33. China Multiple Sclerosis Drugs Revenue Share by Type (2016-2021)
Figure 34. China Multiple Sclerosis Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 35. China Multiple Sclerosis Drugs Revenue Share by Application (2016-2021)
Figure 36. China Multiple Sclerosis Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 37. North America Multiple Sclerosis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 38. North America Multiple Sclerosis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 39. North America Multiple Sclerosis Drugs Sales Market Share by Country in 2020
Figure 40. North America Multiple Sclerosis Drugs Revenue Market Share by Country in 2020
Figure 41. U.S. Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 42. U.S. Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Canada Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 44. Canada Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Europe Multiple Sclerosis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 46. Europe Multiple Sclerosis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 47. Europe Multiple Sclerosis Drugs Sales Market Share by Country in 2020
Figure 48. Europe Multiple Sclerosis Drugs Revenue Market Share by Country in 2020
Figure 49. Germany Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 50. Germany Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. France Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 52. France Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 53. U.K. Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 54. U.K. Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 55. Italy Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 56. Italy Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 57. Russia Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 58. Russia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 59. Asia Pacific Multiple Sclerosis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 60. Asia Pacific Multiple Sclerosis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 61. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region in 2020
Figure 62. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region in 2020
Figure 63. China Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 64. China Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 65. Japan Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 66. Japan Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 67. South Korea Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 68. South Korea Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 69. India Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 70. India Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 71. Australia Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 72. Australia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 73. Taiwan Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 74. Taiwan Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 75. Indonesia Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 76. Indonesia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 77. Thailand Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 78. Thailand Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 79. Malaysia Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 80. Malaysia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 81. Philippines Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 82. Philippines Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 83. Vietnam Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 84. Vietnam Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 85. Latin America Multiple Sclerosis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 86. Latin America Multiple Sclerosis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 87. Latin America Multiple Sclerosis Drugs Sales Market Share by Country in 2020
Figure 88. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country in 2020
Figure 89. Mexico Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 90. Mexico Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 91. Brazil Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 92. Brazil Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 93. Argentina Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 94. Argentina Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 95. Middle East and Africa Multiple Sclerosis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 96. Middle East and Africa Multiple Sclerosis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 97. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country in 2020
Figure 98. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country in 2020
Figure 99. Turkey Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 100. Turkey Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 101. Saudi Arabia Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 102. Saudi Arabia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 103. U.A.E Multiple Sclerosis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 104. U.A.E Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 105. Multiple Sclerosis Drugs Value Chain
Figure 106. Channels of Distribut
  • Global Fingolimod Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Multiple Sclerosis Drugs Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......
  • Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......
  • Fingolimod - Global Market Insights and Sales Trends 2024
    Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77
    The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......
  • Global Fingolimod Market Research Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Global Fingolimod Professional Survey Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024
    Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......
  • Global Multiple Sclerosis Drugs Market Research Report 2023
    Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......
  • Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122
    Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs